Effects of aromatizable and nonaromatizable androgen treatments on luteinizing hormone receptors and ovulation induction in immature rats.
The effects of androgen pretreatment on follicle-stimulating hormone (FSH)-stimulated luteinizing hormone (LH) receptor induction in ovarian granulosa cells was examined. Immature female rats were treated with various doses (0.1-5 mg/rat) of testosterone (T), 5 alpha-dihydrotestosterone (DHT), 5 alpha-androstane-3 alpha,17 beta-diol (3 alpha-diol), or 5 alpha-androstane-3 beta,17 beta-diol (3 beta-diol). Subsequent follicular development was stimulated by treatment with ovine FSH. LH receptor induction in granulosa cells and ovulatory responses to 10 IU human chorionic gonadotropin (hCG) were examined. Since LH receptor induction requires the synergistic action of both FSH and estradiol, the effects of the androgen pretreatment on FSH-stimulated estradiol production were also examined. Dihydrotestosterone treatment at doses greater than 1 mg inhibited LH receptor induction by approximately 70%, which resulted in absent ovulatory responses. Treatment with 1 mg or more of T or 3 alpha-diol had no effect on LH receptor induction, yet the hCG-stimulated ovulation rate was reduced to 40% of that seen in vehicle-treated controls. 3 beta-Diol, at a dose of 1 mg/rat, did not affect LH receptor induction but did reduce hCG-stimulated ovulation responses. No significant effects of androgen treatment on ovarian or uterine weight or FSH-stimulated estradiol production were observed. These results suggest that androgens can act at multiple sites to inhibit ovarian follicular development and function. In addition these studies demonstrate that, although LH receptor induction is necessary, it may not be a sufficient condition to ensure ovulation of ovarian follicles.
D000728:Androgens / Q000008:administration & dosage / Q000494:pharmacology*; D015113:Androstane-3,17-diol / Q000008:administration & dosage / Q000494:pharmacology; D000818:Animals; D013196:Dihydrotestosterone / Q000008:administration & dosage / Q000494:pharmacology; D005260:Female; D005640:Follicle Stimulating Hormone / Q000494:pharmacology*; D006107:Granulosa Cells / Q000187:drug effects; D007986:Luteinizing Hormone / Q000502:physiology*; D009929:Organ Size / Q000187:drug effects; D010053:Ovary / Q000187:drug effects; D010060:Ovulation / Q000187:drug effects*; D010062:Ovulation Induction; D051381:Rats; D011919:Rats, Inbred Strains; D011956:Receptors, Cell Surface / Q000187:drug effects*; D011974:Receptors, LH; D013739:Testosterone / Q000008:administration & dosage / Q000494:pharmacology; D014599:Uterus / Q000187:drug effects
D000728:Androgens; D011956:Receptors, Cell Surface; D011974:Receptors, LH; D013196:Dihydrotestosterone; D015113:Androstane-3,17-diol; D013739:Testosterone; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone